| P2093 | author name string | Jingbo Hu | |
| | Xueying Tan | |
| P2860 | cites work | The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group | Q27861088 |
| | The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes | Q28273497 |
| | Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats | Q28578709 |
| | Biology of incretins: GLP-1 and GIP | Q29617302 |
| | Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future | Q30597265 |
| | A thorough QTc study to assess the effect of sitagliptin, a DPP4 inhibitor, on ventricular repolarization in healthy subjects | Q33482122 |
| | Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas | Q33603384 |
| | Divergent effects of liraglutide, exendin-4, and sitagliptin on beta-cell mass and indicators of pancreatitis in a mouse model of hyperglycaemia | Q34041974 |
| | American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary | Q34081331 |
| | Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers | Q34353892 |
| | Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes | Q34457919 |
| | Evogliptin: First Global Approval | Q34500716 |
| | Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials | Q34633860 |
| | Glucotoxicity and beta-cell failure in type 2 diabetes mellitus | Q35065639 |
| | The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses | Q35120585 |
| | Beneficial Effects of Evogliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, on Adiposity with Increased Ppargc1a in White Adipose Tissue in Obese Mice | Q35860311 |
| | The roles of glycated albumin as intermediate glycation index and pathogenic protein. | Q35911117 |
| | A randomized, double-blind, placebo-controlled, phase II clinical trial to investigate the efficacy and safety of oral DA-1229 in patients with type 2 diabetes mellitus who have inadequate glycaemic control with diet and exercise. | Q36349300 |
| | Islet β cell mass in diabetes and how it relates to function, birth, and death | Q36745536 |
| | Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study. | Q36792608 |
| | Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 |
| | Progression to insulin therapy among patients with type 2 diabetes treated with sitagliptin or sulphonylurea plus metformin dual therapy. | Q37275660 |
| | Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors | Q37598258 |
| | Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control | Q37621774 |
| | Sitagliptin: a review | Q37886184 |
| | Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. | Q37910902 |
| | A review of gliptins in 2011. | Q37965612 |
| | Clinical pharmacokinetics and pharmacodynamics of vildagliptin | Q37984567 |
| | Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis | Q38004088 |
| | Regulating the beta cell mass as a strategy for type-2 diabetes treatment | Q38345256 |
| | Evaluation of the pharmacokinetics, food effect, pharmacodynamics, and tolerability of DA-1229, a dipeptidyl peptidase IV inhibitor, in healthy volunteers: first-in-human study | Q38464759 |
| | Pharmacokinetic study of saxagliptin in healthy Chinese subjects | Q38470357 |
| | Targeted ablation of glucose-dependent insulinotropic polypeptide-producing cells in transgenic mice reduces obesity and insulin resistance induced by a high fat diet | Q39599495 |
| | Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. | Q40667988 |
| | Exendin-4 suppresses SRC activation and reactive oxygen species production in diabetic Goto-Kakizaki rat islets in an Epac-dependent manner | Q41531028 |
| | A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing β-cell replication and neogenesis | Q42480141 |
| | An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials | Q43046357 |
| | Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population | Q43046359 |
| | Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study | Q44631747 |
| | Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury | Q45199143 |
| | Antidiabetic drugs and heart failure risk in patients with type 2 diabetes in the U.K. primary care setting | Q45199358 |
| | The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis | Q46132812 |
| | Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response | Q46747375 |
| | Impact of treatment with saxagliptin on glycaemic stability and β-cell function in the SAVOR-TIMI 53 study. | Q51308310 |
| | Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. | Q51469774 |
| | Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. | Q51483830 |
| | Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. | Q51599426 |
| | DA-1229, a novel and potent DPP4 inhibitor, improves insulin resistance and delays the onset of diabetes. | Q51764065 |
| | Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds | Q57312405 |
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | type 2 diabetes | Q3025883 |
| P304 | page(s) | 1285-1293 | |
| P577 | publication date | 2016-05-09 | |
| P1433 | published in | Expert Opinion on Pharmacotherapy | Q5421212 |
| P1476 | title | Evogliptin: a new dipeptidyl peptidase inhibitor for the treatment of type 2 diabetes | |
| P478 | volume | 17 | |